# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹580 Cr** Q4 FY26 (+9% YoY) · **₹1,798 Cr** FY26 (+1.5% YoY) * **EBITDA:** **₹134 Cr** Q4 FY26 (-5% YoY) · **₹406 Cr** FY26 (-5% YoY) * **OpEx Growth:** **+43%** YoY · **+13%** QoQ ## B. Revenue & Profitability Trends * **Core Growth vs. Trading:** Top-line performance reflects steady single-digit growth, though headline figures include **₹50 Cr** in trading activity and non-core items. * **Margin Resilience:** Despite recent contraction, management maintains a floor for EBITDA margins at **20%**, supported by a long-term growth guidance of **15% to 18%**. * **Earnings Headwinds:** Bottom-line pressure stems from the current heavy investment cycle; however, depreciation impact is expected to ease starting in **FY2028**. * **Accounting Policy:** EBITDA guidance specifically excludes foreign currency fluctuations to better reflect underlying operational health. ## C. Cost Structure & Capacity Ramp-up * **Operational Absorption:** Margins are temporarily suppressed by the "step jump" in costs associated with operationalizing **700 KL** of new capacity across Atali and leased sites. * **Future Cost Escalation:** A further increase in the cost base is anticipated in **Q2 FY2027** following the Xanthine expansion and final capitalization of Atali Phase 1. * **Operating Leverage:** Management expects future revenue from newly commissioned assets to offset the current high manufacturing costs as production scales. ## D. Balance Sheet & Cash Flow * **Working Capital Intensity:** The shift toward large-scale CDMO projects is increasing inventory requirements and manufacturing lead times. * **Self-Financing Pressures:** Cash flow is constrained by the lack of advance payments from major customers, necessitating the self-financing of inventory for infrequent, large-scale deliveries. * **Operational Gains:** Results were bolstered by a **₹22 Cr** net gain on operations derived from favorable export-import balances. --- # 2. Operating Segments ## A. Key Figures * CDMO Revenue: ₹155 Cr Quarterly (+32% YoY) · ₹276 Cr Full Year FY2026 * **Segment Mix (% of Turnover):** **43%** Xanthine · **29%** CDMO · **28%** API & Intermediates ## B. CDMO Segment Performance * **Record Scaling & Pipeline:** Achieved record quarterly performance driven by a robust portfolio of **54 active projects** across **21 customers**, with a strategic shift toward early-phase (Phase 1-3) work. * **Capacity & Guidance:** Management projects aggressive growth of **40% to 50%** for the next year, supported by a single block at Atali with a potential topline of **₹250 Cr to ₹300 Cr**. * **Revenue Recognition & Margins:** Quarterly results were bolstered by a **₹155 Cr** consignment from the previous period; future volume growth may involve lower margin expectations to secure commercial market share. * **Long-term Target:** Aiming for **₹1,000 Cr** in vertical revenue by **FY2028-29**, contingent on customer launch timelines and regulatory approvals. ## C. Xanthine Business Trends * **Volume & Pricing Momentum:** Record quarterly turnover driven by increased volumes and recent price hikes, with a dominant **74%** of volume serving beverage industry leaders. * **Export & Market Dynamics:** Strong global footprint with exports comprising **63%** of sales; however, competitive spot-market pricing may cause EBITDA growth to lag behind revenue expansion. * **Growth Outlook:** Targeting **₹1,000 Cr** revenue in **FY2027**, with peak capacity potential now significantly exceeding that milestone following recent expansions. * **Strategic Cash Cow:** Robust cash flows from this segment are being utilized to self-fund capex, enhancing the company's profile with global innovators. ## D. API & Intermediates Mix * **Cyclical Headwinds:** Segment faced a double-digit decline in FY2026 due to price erosion, inventory destocking, and **feedstock inflation** linked to Middle East geopolitical tensions. * **Recovery Strategy:** Management expects a return to **FY2025** levels (approx. **₹770 Cr**) by **FY2027**, supported by a **30% capacity de-bottlenecking** in steroids. * **Oncology Pivot:** Future growth is anchored by upcoming launches in the anti-cancer space scheduled for **FY2027 and FY2028** to offset persistent competitive pressures. --- # 3. Manufacturing & Capacity ## A. Key Figures * Atali Phase 1 Capacity: 440 kL multi-purpose reactor capacity * **Historical Capex:** **₹450 Cr** Atali greenfield · **₹600 Cr** Last two years cumulative * **Current Production:** **500 tonnes/month** Total output · **6,000 MTPA** Xanthine capacity * **Capacity Growth:** **~70%** Increase in total volume (from **1,000 kL** base) ## B. Atali Project Status * **Operational Readiness:** Phase 1 has resolved startup issues and is slated for full operationalization by the end of the current quarter following customer audits. * **Strategic Positioning:** The facility focuses on intermediates and has secured approvals from several innovators; notably, it does not require US FDA inspection for its current scope. * **Future Scaling:** Management plans to add one new manufacturing block annually at Atali, with future capacity doubling expected to incur lower costs due to established infrastructure. ## C. Capital Expenditure Plans * **Investment Allocation:** The current year's budget is distributed across Xanthine expansion, Atali Phase 2, and debottlenecking at the US FDA-approved Tarapur Unit-4. * **Capex Intensity:** Spending is expected to moderate starting in **FY2028** as major greenfield and brownfield cycles for Xanthine and Atali Phase 1 conclude. * **Risk Mitigation:** CDMO infrastructure is designed with a "repurpose-ready" philosophy, allowing reactors to be transitioned to other uses if specific customer volume forecasts do not materialize. ## D. Asset Utilization & Expansion Strategy * **Capacity Constraints:** The company is currently operating at full utilization for both Xanthine and general plant output, necessitating the current expansion phase. * **Efficiency Gains:** Recent debottlenecking at the Tarapur steroid block increased capacity by **one-third**, with further brownfield expansions for anti-cancer blocks planned for **FY2027**. * **Operational Metrics:** Asset turnover for dedicated blocks is targeted at **1.5x to 2x**, though this may shift if the company integrates more manufacturing stages to capture higher margins. * **Labor Scaling:** Manufacturing footprint expansion is reflected in a significant **50% to 60%** year-over-year increase in total man-hours logged. --- # 4. Commercial & Customer Metrics ## A. Key Figures * **CDMO Revenue Target:** **$100 Million** projected line of sight * **Active CDMO Customers:** **21** stable for five consecutive quarters * **Cost Inflation:** **2x** increase in Xanthine raw materials · **30% to 40%** rise in other materials ## B. Pricing & Cost Pass-through * **Segmented Pass-through Success:** Successfully transferred geopolitical and raw material cost spikes to customers in **CDMO and Xanthine** segments; API and Intermediates remain challenging for existing high-value orders. * **Margin Protection Strategy:** All new inquiries are being quoted at revised higher rates; management is requesting proportionate increases to offset significant raw material inflation. * **Geopolitical Arbitrage:** Leveraging US-China trade tensions and specific tariff structures to implement successful price increases in the **US market**. ## C. Customer & Pipeline Trends * **CDMO Momentum:** While the active client base has remained flat recently, a surge in inquiries following the 2025 slowdown supports expectations for **customer growth** this financial year. * **Pipeline Visibility:** Strong product pipeline and new product launches in **US and European markets** underpin the long-term revenue outlook. --- # 5. Technology & Strategic Initiatives ## A. R&D & New Chemistries * **Portfolio Diversification:** Investing in high-complexity chemistries including **peptides, oligonucleotides, and linkers** to drive long-term value beyond core chemical manufacturing. * **Leadership Strengthening:** Appointment of a **Chief Scientific Officer (CSO)** aims to leverage R&D chemistry expertise to accelerate project acquisition. * **Long-term Horizon:** Management notes that while "tides" investments are currently in the exploration phase, they represent a significant future growth pillar. ## B. China Plus One Strategy * **Supply Chain Diversification:** Successfully capturing US-based demand as customers seek geographic de-risking through the "China Plus One" framework. * **Competitive Moat:** Shortlisted by global CDMO partners due to a **backward integrated model** and the ability to scale production seamlessly from kilo labs to commercial volumes. ## C. Operational Efficiency Gains * **Yield Optimization:** Future margins to be supported by **purpose-built plant expansions** designed to enhance manufacturing yields and solvent recovery. * **Cost Mitigation:** Utilizing advanced **solvent recycling capabilities** at the Atali plant to offset the mid-single-digit inflationary pressures on raw materials. --- # 6. Risks & External Factors ## A. Key Figures * **Net Foreign Exchange Loss (FY26):** **₹33 Cr** Total P&L impact (Notional) * **Quarterly Forex Loss:** **₹17 Cr** Net loss · **₹13 Cr** Specific to one contract ## B. Geopolitical & Logistics Risks * **Inflationary Pressures:** Geopolitical tensions in West Asia have triggered logistics hurdles and rising energy costs, straining overall profitability. * **Varied Pricing Power:** While the intermediate segment faces challenges passing on costs, other business units have successfully implemented **customer price hikes** to offset inflation. * **Margin Sensitivity:** Future EBITDA margins remain highly sensitive to the West Asia crisis, global conflicts, and Rupee volatility. ## C. Foreign Exchange Volatility * **Non-Cash Impact:** The significant annual forex hit is primarily a **notional loss** tied to foreign currency term loans rather than a realized cash outflow. * **Loss Composition:** The quarterly net loss is a aggregate of operational gains (export/import net), losses on currency contracts, and higher costs on **foreign currency loans**. * **Risk Mitigation:** Management has accounted for all potential impacts, with no unaccounted forward contracts extending beyond the next **six to eight months**. ## D. Competitive Pricing Pressures * **Portfolio Optimization:** The company anticipates potential price increases for high-strength products, contingent upon the specific **competitive landscape** for each molecule. --- # 7. Guidance & Outlook ## A. Key Figures * **Long-term Growth Target:** **15% to 18%** Revenue & EBITDA CAGR (3-4 Year Horizon) * **CDMO/CMO Growth:** **40% to 50%** Projected Sales Increase for FY2027 * **Xanthine Capacity:** **6,000 MTPA** to **9,000 MTPA** phased ramp-up ## B. Long-term Growth Targets * **Strategic Capacity Positioning:** Management is proactively expanding reactor volumes and manufacturing footprints to secure capacity ahead of project commercialization. * **Guidance Philosophy:** The company prioritizes multi-year outlooks over specific annual targets for FY2027 due to the inherent volatility in **CDMO/CMO customer approval timelines**. * **Outlook Evaluation:** Current mid-term projections are being reassessed against recent CapEx to determine if the existing guidance remains **conservative**. ## C. Capacity Ramp-up Timeline * **Xanthine Expansion:** Incremental capacity for derivatives is scheduled to come online at the end of the current quarter, scaling production over the coming months. * **Atali Site Commencement:** Full-fledged operations at the Atali facility are slated for **June 2026**, contingent upon the completion of necessary audits. * **Margin Normalization Lag:** Management anticipates a **one-year gestation period** for new capital expenditures to meaningfully impact EBITDA and margin profiles.